그린위치 라이프사이언스(GLSI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $18.99 (+3.26%), 시가총액 $0.38B, 52주 최저~최고 $7.85 ~ $33.56.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018
그린위치 라이프사이언스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
그린위치 라이프사이언스의 현재 주가는 $18.99 (+3.26%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
그린위치 라이프사이언스의 시가총액은 약 $0.38B입니다.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania